Trends in clinical success rates

Cited by (277)

Items 101–200 of 277

1. A comprehensive review of discovery and development of drugs discovered from 2020–2022
   Usman Shareef, Aisha Altaf, Madiha Ahmed, Nosheen Akhtar, Mohammed Saad Almuhayawi, Soad Khalil Al Jaouni, Samy Selim, Mohamed Abdelwahab Abdelgawad, Mohammed Kamal Nagshabandi · 2023 · Saudi Pharmaceutical Journal
2. How Biologics Have Changed the Drug Discovery Landscape
   Paul McGonigle · 2024 · The Annual Review of Pharmacology and Toxicology
3. Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US
   Olivier J. Wouters, Matthew Vogel, William B. Feldman, Reed F. Beall, Aaron Seth Kesselheim, S. Sean Tu · 2024 · JAMA
4. The design and characterization of a gravitational microfluidic platform for drug sensitivity assay in colorectal perfused tumoroid cultures
   Tao Wang, Ryan J. Green, Mark Howell, Taylor E. Martinez, Rinku Dutta, Subhra Mohapatra, Shyam S. Mohapatra · 2020 · Nanomedicine Nanotechnology Biology and Medicine
5. A structure-based computational workflow to predict liability and binding modes of small molecules to hERG
   Subha Kalyaanamoorthy, Shawn M. Lamothe, Xiaoqing Hou · 2020 · Scientific Reports
6. Segmentation of Drug‐Treated Cell Image and Mitochondrial‐Oxidative Stress Using Deep Convolutional Neural Network
   Awais Khan Nawabi, Jinfang Sheng, Rashid Abbasi · 2022 · Oxidative Medicine and Cellular Longevity
7. All‐in‐one microfluidic design to integrate vascularized tumor spheroid into high‐throughput platform
   Youngtaek Kim, Jihoon Ko, Nari Shin, Seonghyuk Park, Byungjun Lee, Suryong Kim, Jiyoung Song, Seok-Jun Lee, Kyung‐Sun Kang, Jeeyun Lee et al. · 2022 · Biotechnology and Bioengineering
8. Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders
   Xiaoyan Li, Aotian Shen, Yiran Zhao, Junfeng Xia · 2023 · Schizophrenia Bulletin
9. Multiscale Profiling of Nanoscale Metal‐Organic Framework Biocompatibility and Immune Interactions
   Yunhui Zhuang, Bárbara B. Mendes, Dhruv Menon et al. · 2025 · Advanced Healthcare Materials
10. Progress of AI-Driven Drug–Target Interaction Prediction and Lead Optimization
    Qiqi Wang, Boyan Sun, Yunpeng Yi, Tony Velkov, Jianzhong Shen, Chongshan Dai, Haiyang Jiang · 2025 · International Journal of Molecular Sciences
11. International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies
    Fumio Teramae, Tomohiro Makino, Yeongjoo Lim, Shintaro Sengoku, Kota Kodama · 2020 · Sustainability
12. Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs
    Chi Heem Wong, Kien Wei Siah, Andrew W. Lo · 2020 · Harvard Data Science Review
13. Using data analytics to accelerate biopharmaceutical process scale-up
    Pierantonio Facco, Simeone Zomer, Ruth C. Rowland‐Jones, Douglas Marsh, Paloma Diaz‐Fernandez, Gary Finka, Fabrizio Bezzo, Massimiliano Barolo · 2020 · Biochemical Engineering Journal
14. Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal
    Andrew M. Thompson, Patrick D. O’Connor, Andrew J. Marshall et al. · 2020 · European Journal of Medicinal Chemistry
15. TSSF-hERG: A machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction
    Jinhui Meng, Li Zhang, Lian-Xin Wang, Shimeng Li, Di Xie, Yuxi Zhang, Hongsheng Liu · 2021 · Toxicology
16. GelMA hydrogel: A game-changer in 3D tumor modeling
    Weijie Jiao, Jingxin Shan, Xue Gong, Yuanyuan Sun, Lin Sang, Xiaoying Ding, Huihui Zhou, Ming Yu · 2024 · Materials Today Chemistry
17. Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
    Meiko Nishimura, Mitsuhiro Hayashi, Yu Mizutani et al. · 2018 · Oncotarget
18. Using Mendelian randomization to understand and develop treatments for neurodegenerative disease
    Catherine S. Storm, Demis A. Kia, Mona Mohammad Almramhi, Nicholas William Wood · 2020 · Brain Communications
19. Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials
    John J. Warner, Hannah L. Crook, Karley Whelan, William K. Bleser, Rachel A. Roiland, Marianne Hamilton Lopez, Robert S. Saunders, Tracy Y. Wang, Adrian F. Hernandez, Mark McClellan et al. · 2020 · Circulation Cardiovascular Quality and Outcomes
20. Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
    Kaela Kelly, Andrew B. West · 2020 · Frontiers in Neuroscience
21. Ligandomics: a paradigm shift in biological drug discovery
    Wěi Li, Iok-Hou Pang, Mário Thiego Fernandes Pacheco, Hong Tian · 2018 · Drug Discovery Today
22. Insights into mechanisms and severity of drug-induced liver injury via computational systems toxicology approach
    Yayuan Peng, Zengrui Wu, Hongbin Yang, Yingchun Cai, Guixia Liu, Weihua Li, Yun Tang · 2019 · Toxicology Letters
23. Strategies to Mitigate the Bioactivation of Aryl Amines
    Chenghong Zhang, James J. Crawford, Matthew L. Landry, Huifen Chen, Jane R. Kenny, Siamak Cyrus Khojasteh, Wendy Lee, Shuguang Ma, Wendy B. Young · 2020 · Chemical Research in Toxicology
24. Current Drug Discovery
    Jeffrey J. Hale · 2022 · Wiley eBooks
25. Dynamic clinical trial success rates for drugs in the 21st century
    Ying Zhou, Yintao Zhang, Hangwei Xu, Zhen Chen, Shijie Huang, Yinghong Li, Jianbo Fu, Hongning Zhang, Donghai Zhao, Xichen Lian et al. · 2025 · Nature Communications
26. Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies
    Fumio Teramae, Tomohiro Makino, Yeongjoo Lim, Shintaro Sengoku, Kota Kodama · 2020 · Sustainability
27. Estimating Clinical Trial Success Rates and Related Parameters in Oncology
    Chi Heem Wong, Kien Wei Siah, Andrew W. Lo · 2019 · SSRN Electronic Journal
28. Data-driven toxicity prediction in drug discovery: Current status and future directions
    Ningning Wang, Xinliang David Li, Jing Xiao, Shao Liu, Dongsheng Cao · 2024 · Drug Discovery Today
29. Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value
    Jean‐Paul Gaudillière · 2021 · BioSocieties
30. Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics
    Giuseppe Licari, Kyle Martin, Maureen Crames, Joseph Mozdzierz, Michael S. Marlow, Anne R. Karow‐Zwick, Sandeep Kumar, Joschka Bauer · 2022 · Molecular Pharmaceutics
31. The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience
    Dalia Karol, Mathieu McKinnon, Lenah E. Mukhtar · 2021 · Frontiers in Oncology
32. Pharmacological vs. classical approaches in the design of first in man clinical drug trials
    Cornelis A. van den Bogert, Adam F. Cohen, Hubert G. M. Leufkens, Joop van Gerven · 2017 · British Journal of Clinical Pharmacology
33. Developing an Improved Risk-Adjusted Net Present Value Technology Valuation Model for the Biopharmaceutical Industry
    Jonghak Woo, Eungdo Kim, Tae-Eung Sung · 2019 · Journal of Open Innovation Technology Market and Complexity
34. Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility
    Andrew M. Thompson, Patrick D. O’Connor, Vanessa Yardley et al. · 2021 · ACS Medicinal Chemistry Letters
35. In-depth understanding of the structure-based reactive metabolite formation of organic functional groups
    Chunyong He, Yuchang Mao, Hong Wan · 2025 · Drug Metabolism Reviews
36. Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans
    Isaac T. W. Harley, Kristen Allison, Robert Hal Scofield · 2022 · Frontiers in Immunology
37. Reconstructed Human Epidermis Predicts Barrier-Improving Effects of Lactococcus lactis Emulsion in Humans
    Christian Hausmann, Dominique Hertz-Kleptow, Christian Zoschke, Barbara Wanjiku, Alexandra Wentzien-Odenthal, Martina J. Kerscher, Monika Schäfer‐Korting · 2019 · Skin Pharmacology and Physiology
38. Integrating sequence and graph information for enhanced drug-target affinity prediction
    Haohuai He, Guanxing Chen, Calvin Yu‐Chian Chen · 2024 · Science China Information Sciences
39. Machine learning & deep learning tools in pharmaceutical sciences: A comprehensive review
    Saleem Javid, Abdul Rahmanulla, Mohammed Gulzar Ahmed, Rokeya Sultana, B. R. Prashantha Kumar · 2025 · Intelligent Pharmacy
40. The emergence of AntibodyPlus: the future trend of antibody-based therapeutics
    Yong Zhu, Shawn Shouye Wang, Zhaohui Sunny Zhou, Mitchell Ho · 2022 · Antibody Therapeutics
41. The Scientific Problems with Using Non-Human Animals to Predict Human Response to Drugs and Disease
    Ray Greek, Lisa A. Kramer · 2019 · BRILL eBooks
42. Medicines discovery for auditory disorders: Challenges for industry
    Rick P. C. Cousins · 2019 · The Journal of the Acoustical Society of America
43. Improving the Prediction of Clinical Success Using Machine Learning
    Bernard H. Munos, Jan Niederreiter, Massimo Riccaboni · 2021 · medRxiv
44. Role of Diverse Smooth Muscle Cell Phenotypic Transitions in Atherosclerosis Development and Late-Stage Pathogenesis
    Vlad Serbulea, James Martin, Gary K. Owens · 2025 · Annual Review of Physiology
45. Perspectives on the clinical use of anti‐amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology
    Gregory A. Jicha, Erin L. Abner, Elif Pinar Coskun, Mark J. Huffmyer, Thomas C. Tucker, Peter T. Nelson · 2024 · Alzheimer s & Dementia Translational Research & Clinical Interventions
46. Neural circuits of eating behaviour: Opportunities for therapeutic development
    Peter G. Clifton · 2017 · Journal of Psychopharmacology
47. 3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations
    Virginia Guzzeloni, Lorenzo Veschini, Federica Pedica, Elisabetta Ferrero, Marina Ferrarini · 2022 · Antibodies
48. Prediction of the pharmacokinetics of the GLP-1 receptor agonist semaglutide in humans via a population pharmacokinetic model integrating interspecies scaling
    Joonhee Kim, Keon Kim, Tae Suk Lee, Hyunmin Cho, Seung-Dong Yoo, Tae‐Hwan Kim, Beom Soo Shin, Soyoung Shin · 2024 · Journal of Pharmaceutical Investigation
49. Brain Organoids: Tools for Understanding the Uniqueness and Individual Variability of the Human Brain
    Irene Faravelli, Noelia Antón-Bolaños, Juliana R. Brown, Paola Arlotta · 2025 · Annual Review of Genomics and Human Genetics
50. Complex injectables
    Abhijeet P. Pandey, Debjani Singh, Namdev L. Dhas, Akhilesh Kumar Tewari, Kamla Pathak, Vivekanand Kisan Chatap, Kamal Singh Rathore, Srinivas Mutalik · 2020 · Elsevier eBooks
51. Stress-dependent Flexibility of a Full-length Human Monoclonal Antibody: Insights from Molecular Dynamics to Support Biopharmaceutical Development
    Dheeraj S. Tomar, Giuseppe Licari, Joschka Bauer, Satish Kumar Singh, Li Li, Sandeep Kumar · 2021 · Journal of Pharmaceutical Sciences
52. Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs
    Andrew W. Lo, Kien Wei Siah, Chi Heem Wong · 2020 · National Bureau of Economic Research
53. Diffusion Models at the Drug Discovery Frontier: A Review on Generating Small Molecules Versus Therapeutic Peptides
    Yiquan Wang, Yahui Ma, Yu-Han Chang, Jiayao Yan, Jialin Zhang, Ming-Yi Cai, Kai Wei · 2025 · Biology
54. Continuous Flow Conditions for High Temperature Formation of a Benzodioxan Pharmaceutical Intermediate: Rapid Scaleup for Early Phase Material Delivery
    Pengbin Li, Shaohui Yang, Ruiheng Zhu · 2020 · Organic Process Research & Development
55. A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis
    Katherine A. Cummins, Peter B. Bitterman, Daniel J. Tschumperlin, David K. Wood · 2021 · APL Bioengineering
56. A novel perspective on pharmaceutical R&D costs: opportunities for reductions
    Simon van der Schans, Frans De Loos, Cornelis Boersma · 2021 · Expert Review of Pharmacoeconomics & Outcomes Research
57. Patient-derived tumoroids and proteomic signatures: tools for early drug discovery
    Hélène Lê, Jules Deforges, Pasquale Cutolo, Anissa Lamarque, Guoqiang Hua, Véronique Lindner, Shreyansh Jain, Jean‐Marc Balloul, Nadia Benkirane-Jessel, Éric Quéméneur · 2024 · Frontiers in Immunology
58. Consideration of the Root Causes in Candidate Attrition During Oncology Drug Development
    Yin‐Ming Kuo, Jeffrey S. Barrett · 2024 · Clinical Pharmacology in Drug Development
59. Pharmacological Potential of Pyrmidine Derivatives: A Review With Emphasis on Antiviral Effects and Virtual Screening Against Sars‐Cov‐2 Molecular Targets
    Erick Costa, Zenaide Severina do Monte, Emerson P. S. Falcão, Mayara dos Santos Maia, Renata Priscila Barros de Menezes, Luciana Scotti, Marcus Tullius Scotti, Sebastiao Jose de Melo · 2023 · ChemistrySelect
60. Late-stage Product Development and Approvals by Biotechnology Companies After Initial Public Offering, 1997–2016
    Laura M. McNamee, Ekaterina Galkina Cleary, Sunyi Zhang, Usama Salim, Fred David Ledley · 2020 · Clinical Therapeutics
61. CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials
    Jan Rekowski, Christina W. Guo, Olga Solovyeva, Munyaradzi Dimairo, Mahtab Rouhifard, Dhrusti Patel, Emily Alger, Deborah Ashby, Jordan D. Berlin, Oliver Boix et al. · 2025 · EClinicalMedicine
62. Biomaterial-driven regenerative drug delivery: a vicennial bibliometric landscape
    Xin Shen, Haobin Deng, Jing Lin, Jianhua Wang, Yilun Liu, Shikun Mo · 2025 · Frontiers in Medicine
63. The evolving global landscape of first-in-class oncology drug innovation
    Xiangyun Mao, Zhaoqing Wang, Shu Kong, Yue Yang, Nancy A Dreyer, Yi Ba, Michael T. Lotze, Qimin Zhan, Guanqiao Li · 2026 · Signal Transduction and Targeted Therapy
64. GCLmf: A Novel Molecular Graph Contrastive Learning Framework Based on Hard Negatives and Application in Toxicity Prediction**
    Xinxin Yu, Yuanting Chen, Long Chen, Weihua Li, Yuhao Wang, Yun Tang, Guixia Liu · 2024 · Molecular Informatics
65. Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone
    Brenna C. McAllister, Nooshin Mesbahi, Esther E. Dodson, Sakinah Abdulsalam, Clifford E. Berkman, Leslie Ann Caromile · 2024 · Frontiers in Oncology
66. Exploratory Analysis of the Factors Associated With Success Rates of Confirmatory Randomized Controlled Trials in Cancer Drug Development
    Can Wu, Shunsuke Ono · 2020 · Clinical and Translational Science
67. A Brainer on Neurotoxicity
    Ellen Fritsche, Helena T. Högberg · 2020 · Frontiers in Toxicology
68. Human Forest vs. Random Forest in Time-Sensitive COVID-19 Clinical Trial Prediction
    Pavel Dimitrov Atanasov, Regina Joseph, Felipe Feijoo, Max Marshall, Amanda Conway, Sauleh Siddiqui · 2021 · SSRN Electronic Journal
69. Accelerating biopharmaceutical cell line selection with label-free multimodal nonlinear optical microscopy and machine learning
    Jindou Shi, Alexander Ho, Corey E. Snyder, Eric James Chaney, Janet Elise Sorrells, Aneesh Alex, Remben V. Talaban, Darold R. Spillman, Marina Marjanović, Minh Doan et al. · 2025 · Communications Biology
70. Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations
    Rajiv G. Raja, Young Shin Lee, Katie L. Streicher, James Conway, Song Wu, Sriram Sridhar, Mike Kuziora, Hao Liu, Brandon W. Higgs, Philip Z. Brohawn et al. · 2017 · Pharmaceutical Medicine
71. Development of a 3-D Organoid System Using Human Induced Pluripotent Stem Cells to Model Idiopathic Autism
    Jason W. Lunden, Madel Durens, Jonathan E. Nestor, Robert F. Niescier, Kevin Herold, Cheryl Brandenburg, Yu‐Chih Lin, Gene J. Blatt, Michael W. Nestor · 2020 · Advances in neurobiology
72. Convergence of artificial intelligence and nanotechnology in the development of novel formulations for cancer treatment
    Abid Naeem, Muhammad Suhail, Abdul Basit, Liu Yali, Zhang Ming Xia, Zheng Qin, Yang Ming · 2023 · Elsevier eBooks
73. Fully Liquid Phase Oligonucleotide Synthesis
    Piers R. J. Gaffney, Charles Jarrett-Wilkins, Jet Yeo et al. · 2025 · Organic Process Research & Development
74. Natural Products in Precision Neurological Disease (Cryptococcal Meningitis): Structure‐Based Phytochemical Screening of Glycyrrhiza glabra Plant Against Cryptococcus neoformans Farnesyltransferase (FTase)
    Noimul Hasan Siddiquee, Md. Shiful Islam Sujan, Tasnuva Islam Dremit et al. · 2024 · Chemistry & Biodiversity
75. MALDI Imaging and Spatial SILAC Proteomics of Three-Dimensional Multicellular Spheroids Dynamically Dosed with Doxorubicin-Encapsulating Liposomes
    Arbil Lopez, Joseph H. Holbrook, Amanda B. Hummon · 2025 · Analytical Chemistry
76. Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?
    Marcela Vieira, Ryan Kimmitt, Suerie Moon · 2021 · F1000Research
77. Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment
    Kenneth R. Gundle, Karthik Rajasekaran, Jeffrey J. Houlton et al. · 2024 · Frontiers in Pharmacology
78. Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations
    David G. Proudman, Urvi S. Desai, Dumingu Aparna Gomes, Maks Khomenko, Silas Martin, Dave Nellesen, Ulrich Neumann, Henry G. Grabowski · 2024 · Journal of Medical Economics
79. Combining Single-Cell RNA Sequencing and Mendelian Randomization to Explore Novel Drug Targets for Parkinson’s Disease
    Xiaolong Wu, Kailiang Wang, Qinghua Li, Yuqing Zhang, Penghu Wei, Yongzhi Shan, Guoguang Zhao · 2025 · Molecular Neurobiology
80. Does Firm’s Alliances Increase New Drug Development Time? A Multiple Regression Analysis of Clinical Development Time
    Ho-Kyoung Kim, Hyesung Lee, Sangwon Lee · 2023 · Journal of Pharmaceutical Innovation
81. From academia to industry: a road more travelled
    William J. Pao · 2017 · Annals of Oncology
82. The reproducibility issue and preclinical academic drug discovery: educational and institutional initiatives fostering translation success
    David R. Janero · 2016 · Expert Opinion on Drug Discovery
83. What's Past Is Prologue: Clinical Pharmacology at the Intersection of Science, Policy, and Patients
    Issam Zineh, Dan Hartman · 2019 · Clinical Pharmacology & Therapeutics
84. Editorial: Use of quantitative systems pharmacology pipelines to bridge in vitro and in vivo results in drug discovery
    Federico Reali, Attila Csikász‐Nagy, Gianluca Selvaggio · 2023 · Frontiers in Systems Biology
85. Exploring druggable targets and inflammation-mediated pathways in cancer: a Mendelian randomization analysis integrating transcriptomic and proteomic data
    Hao Pan, Changqing Jing · 2025 · Inflammation Research
86. Development of Highly Chemoselective Oxidative Transformations by Designing Organoradicals
    Kounosuke Oisaki · 2018 · Chemical and Pharmaceutical Bulletin
87. Human-relevant preclinical in vitro models for studying hepatobiliary development and liver diseases using induced pluripotent stem cells
    Pooja Chaudhari, Lipeng Tian, Zhaohui Ye, Yoon-Young Jang · 2019 · Experimental Biology and Medicine
88. 11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells
    Tania Aguado, Jose A. Romero‐Revilla, Rosario Granados, Susana Campuzano, Rebeca Magnolia Torrente-Rodríguez, Ángel M. Cuesta, Virginia Albiñana, Luisa M. Botella, Silvia Santamaría Santamaría, José A. García‐Sanz et al. · 2019 · Scientific Reports
89. Mechanistic Image-Based Modelling: Concepts and Applications
    Denis Menshykau, Simon Tanaka · 2019 · Handbook of experimental pharmacology
90. Warning About Shortcuts in Drug Development
    Robert M. Califf · 2017 · Journal of the American Heart Association
91. New Trends in Drug Discovery
    Gerd Schnorrenberg · 2018 · Wiley eBooks
92. Finding drug targeting mechanisms with genetic evidence for Parkinson’s disease
    Catherine S. Storm, Demis A. Kia, Mona Mohammad Almramhi, Sara Bandrés‐Ciga, Chris Finan, Aroon Dinesh Hingorani, Nicholas William Wood · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
93. Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
    Catherine S. Storm, Demis A. Kia, Mona Mohammad Almramhi, Dilan S. Athauda, Stephen Burgess, Thomas Foltynie, Nicholas William Wood · 2020 · medRxiv
94. Predicting Success of Phase III Trials in Oncology
    Stephan J Hegge, Markus Thunecke, Matthias Krings, Leonard Ruedin, Jan Saputra Mueller, Paul von Bünau · 2020 · medRxiv
95. An approach to produce thousands of single-chain antibody variants on a SPR biosensor chip for measuring target binding kinetics and for deep characterization of antibody paratopes
    Rebecca L. Cook, William Martelly, Chidozie Victor Agu, Lydia R. Gushgari, Salvador Moreno, Sailaja Kesiraju, Mukilan Mohan, Bharath R. Takulapalli · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
96. Combining AI design and molecular dynamics to disrupt amyloid aggregation in Alzheimer’s disease
    Ayla Esmaeilzadeh, Maryam Azimzadeh Irani, Ali Javanmard, Mahdiyeh Gharaei Khezri · 2026 · Discover Applied Sciences
97. Antibacterial Drug Discovery: Deep Learning Successes and Challenges through the Structural Biology Lens
    Jameel M. A. Abduljalil, Sandro F. Ataide, Ann H. Kwan · 2026 · Computational and Structural Biotechnology Journal
98. Analysis of Nutrition Clinical Studies Involving Children in the Middle East and Globally
    Fatih Özdener, Feza Kırbıyık, Ali Evrim Doğan · 2018 · Future Science OA
99. A Comparative Study on the SWOG Two-Stage Design Extension to Stop Early for Efficacy in Single Arm Phase II Trials
    Monica Chaudhari, John Crowley, Antje Hoering · 2020 · Statistics in Biopharmaceutical Research
100. Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review
     Giacomo Bregni, Elena Trevisi, Rita Saúde Conde · 2023 · JNCI Journal of the National Cancer Institute